{
 "disease": "hepatocellular-carcinoma",
 "label": "Hepatocellular carcinoma",
 "url": "https://usebiotransfer.org/disease/hepatocellular-carcinoma/",
 "built": "2026-09-08",
 "facts_hash": {
  "answers": "19b640293faf",
  "targets": "c81784024978"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-08",
  "trials": "2026-09-08"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "TERT",
   "ensembl": "ENSG00000164362",
   "n_drug_entries": 2,
   "n_distinct_drugs": 1,
   "drugs": {
    "IMETELSTAT": "APPROVAL"
   },
   "approved": [
    "IMETELSTAT"
   ],
   "n_approved": 1,
   "approved_for": {
    "IMETELSTAT": [
     "anemia",
     "myelodysplastic syndrome"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CTNNB1",
   "ensembl": "ENSG00000168036",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "PRI-724": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "AXIN1",
   "ensembl": "ENSG00000103126",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "ARID1A",
   "ensembl": "ENSG00000117713",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "MET",
   "ensembl": "ENSG00000105976",
   "n_drug_entries": 38,
   "n_distinct_drugs": 36,
   "drugs": {
    "ALTIRATINIB": "PHASE_1",
    "AMG-208": "PHASE_2",
    "AMG-337": "PHASE_2",
    "AMIVANTAMAB": "APPROVAL",
    "AMUVATINIB": "PHASE_2",
    "ARRY-300": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BEPERMINOGENE PERPLASMID": "PHASE_3",
    "BMS-777607": "PHASE_1_2",
    "BMS-817378": "PHASE_1",
    "BPI-9016": "PHASE_1",
    "CABOZANTINIB": "APPROVAL",
    "CABOZANTINIB S-MALATE": "APPROVAL",
    "CAPMATINIB": "APPROVAL",
    "CRIZOTINIB": "APPROVAL",
    "EMD-1204831": "PHASE_1",
    "EMIBETUZUMAB": "PHASE_2",
    "FORETINIB": "PHASE_2",
    "GLESATINIB": "PHASE_2",
    "GOLVATINIB": "PHASE_1_2",
    "JNJ-38877605": "PHASE_1",
    "MERESTINIB": "PHASE_2",
    "MK-2461": "PHASE_1_2",
    "MK-8033": "PHASE_1",
    "NINGETINIB": "PHASE_2",
    "ONARTUZUMAB": "PHASE_3",
    "PF-04217903": "PHASE_1",
    "SAR-125844": "PHASE_2",
    "SAVOLITINIB": "PHASE_3",
    "SGX-523": "PHASE_1",
    "TAS-115": "PHASE_1",
    "TELISOTUZUMAB": "PHASE_1",
    "TELISOTUZUMAB VEDOTIN": "PHASE_3",
    "TEPOTINIB": "APPROVAL",
    "TEREVALEFIM": "PHASE_3",
    "TIVANTINIB": "PHASE_3"
   },
   "approved": [
    "AMIVANTAMAB",
    "CABOZANTINIB",
    "CABOZANTINIB S-MALATE",
    "CAPMATINIB",
    "CRIZOTINIB",
    "TEPOTINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "CABOZANTINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "hepatocellular carcinoma",
     "renal cell carcinoma",
     "medullary thyroid gland carcinoma"
    ],
    "CABOZANTINIB S-MALATE": [
     "thyroid gland carcinoma",
     "renal cell carcinoma"
    ],
    "CAPMATINIB": [
     "non-small cell lung carcinoma"
    ],
    "CRIZOTINIB": [
     "non-small cell lung carcinoma"
    ],
    "TEPOTINIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "FGF19",
   "ensembl": "ENSG00000162344",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    }
   ]
  },
  {
   "symbol": "FGFR4",
   "ensembl": "ENSG00000160867",
   "n_drug_entries": 17,
   "n_distinct_drugs": 16,
   "drugs": {
    "ALDAFERMIN": "PHASE_2_3",
    "BRIVANIB": "PHASE_3",
    "BRIVANIB ALANINATE": "PHASE_3",
    "DERAZANTINIB": "PHASE_3",
    "ENMD-981693": "PHASE_2",
    "ERDAFITINIB": "APPROVAL",
    "FEXAGRATINIB": "PHASE_2",
    "FGF401": "PHASE_1_2",
    "FUTIBATINIB": "APPROVAL",
    "INFIGRATINIB": "APPROVAL",
    "LY-2874455": "PHASE_2",
    "NINTEDANIB": "APPROVAL",
    "NINTEDANIB ESYLATE": "APPROVAL",
    "ORANTINIB": "PHASE_3",
    "ROGARATINIB": "PHASE_2_3",
    "XL-999": "PHASE_2"
   },
   "approved": [
    "ERDAFITINIB",
    "FUTIBATINIB",
    "INFIGRATINIB",
    "NINTEDANIB",
    "NINTEDANIB ESYLATE"
   ],
   "n_approved": 5,
   "approved_for": {
    "ERDAFITINIB": [
     "urothelial carcinoma",
     "urinary bladder carcinoma"
    ],
    "FUTIBATINIB": [
     "biliary tract cancer",
     "intrahepatic cholangiocarcinoma",
     "cholangiocarcinoma"
    ],
    "INFIGRATINIB": [
     "cholangiocarcinoma"
    ],
    "NINTEDANIB": [
     "idiopathic pulmonary fibrosis",
     "colorectal cancer",
     "interstitial lung disease",
     "systemic sclerosis",
     "pulmonary fibrosis"
    ],
    "NINTEDANIB ESYLATE": [
     "idiopathic pulmonary fibrosis",
     "systemic sclerosis",
     "non-small cell lung carcinoma",
     "Interstitial pneumonitis"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "KDR",
   "ensembl": "ENSG00000128052",
   "n_drug_entries": 75,
   "n_distinct_drugs": 70,
   "drugs": {
    "4SC-203": "PHASE_1",
    "AEE-788": "PHASE_1_2",
    "ALACIZUMAB PEGOL": "PHASE_2",
    "ALTIRATINIB": "PHASE_1",
    "AXITINIB": "APPROVAL",
    "BFH-772": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BMS-817378": "PHASE_1",
    "BRIVANIB": "PHASE_3",
    "BRIVANIB ALANINATE": "PHASE_3",
    "CABOZANTINIB": "APPROVAL",
    "CABOZANTINIB S-MALATE": "APPROVAL",
    "CATEQUENTINIB": "PHASE_3",
    "CEDIRANIB": "APPROVAL",
    "CEP-11981": "PHASE_2",
    "CEP-5214": "UNKNOWN",
    "CM-082": "PHASE_2",
    "CYC-116": "PHASE_1",
    "DOVITINIB": "PHASE_3",
    "ENMD-2076": "PHASE_2",
    "ENMD-981693": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "FRUQUINTINIB": "APPROVAL",
    "GLESATINIB": "PHASE_2",
    "GOLVATINIB": "PHASE_1_2",
    "HENATINIB": "PHASE_1",
    "IBCASERTIB": "PHASE_3",
    "ILORASERTIB": "PHASE_2",
    "IMC-1C11": "PHASE_1",
    "JI-101": "PHASE_2",
    "KRN-633": "PHASE_1",
    "LENVATINIB": "APPROVAL",
    "LINIFANIB": "PHASE_3",
    "LUCITANIB": "PHASE_3",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "NINGETINIB": "PHASE_2",
    "NINTEDANIB": "APPROVAL",
    "NINTEDANIB ESYLATE": "APPROVAL",
    "OLINVACIMAB": "PHASE_2",
    "ORANTINIB": "PHASE_3",
    "OSI-632": "PHASE_2",
    "OSI-930": "PHASE_1",
    "PAZOPANIB": "APPROVAL",
    "PEGDINETANIB": "PHASE_2",
    "PF-00337210": "PHASE_1",
    "RAF-265": "PHASE_2",
    "RAMUCIRUMAB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RG-1530": "PHASE_1",
    "RIVOCERANIB": "APPROVAL",
    "SEMAXANIB": "PHASE_3",
    "SORAFENIB": "APPROVAL",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "SURUFATINIB": "APPROVAL",
    "TAK-593": "PHASE_1",
    "TAS-115": "PHASE_1",
    "TELATINIB": "PHASE_2",
    "TELBERMIN": "PHASE_2",
    "TG100-801": "PHASE_2",
    "TIVOZANIB": "APPROVAL",
    "VANDETANIB": "APPROVAL",
    "VATALANIB": "PHASE_3",
    "X-82": "PHASE_2",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2",
    "ZD-4190": "UNKNOWN"
   },
   "approved": [
    "AXITINIB",
    "CABOZANTINIB",
    "CABOZANTINIB S-MALATE",
    "CEDIRANIB",
    "FRUQUINTINIB",
    "LENVATINIB",
    "MIDOSTAURIN",
    "NINTEDANIB",
    "NINTEDANIB ESYLATE",
    "PAZOPANIB",
    "RAMUCIRUMAB",
    "REGORAFENIB",
    "RIVOCERANIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "SURUFATINIB",
    "TIVOZANIB",
    "VANDETANIB"
   ],
   "n_approved": 19,
   "approved_for": {
    "AXITINIB": [
     "renal cell carcinoma"
    ],
    "CABOZANTINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "hepatocellular carcinoma",
     "renal cell carcinoma",
     "medullary thyroid gland carcinoma"
    ],
    "CABOZANTINIB S-MALATE": [
     "thyroid gland carcinoma",
     "renal cell carcinoma"
    ],
    "CEDIRANIB": [],
    "FRUQUINTINIB": [
     "colorectal cancer",
     "colorectal neoplasm"
    ],
    "LENVATINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "renal cell carcinoma",
     "differentiated thyroid carcinoma",
     "thyroid gland carcinoma"
    ],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "NINTEDANIB": [
     "idiopathic pulmonary fibrosis",
     "colorectal cancer",
     "interstitial lung disease",
     "systemic sclerosis",
     "pulmonary fibrosis"
    ],
    "NINTEDANIB ESYLATE": [
     "idiopathic pulmonary fibrosis",
     "systemic sclerosis",
     "non-small cell lung carcinoma",
     "Interstitial pneumonitis"
    ],
    "PAZOPANIB": [
     "soft tissue sarcoma",
     "renal cell carcinoma",
     "sarcoma"
    ],
    "RAMUCIRUMAB": [
     "gastric cancer",
     "non-small cell lung carcinoma",
     "gastric adenocarcinoma",
     "gastric neoplasm",
     "gastroesophageal junction adenocarcinoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIVOCERANIB": [
     "breast cancer"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "thyroid gland carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "SURUFATINIB": [],
    "TIVOZANIB": [
     "renal cell carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "VEGFA",
   "ensembl": "ENSG00000112715",
   "n_drug_entries": 14,
   "n_distinct_drugs": 13,
   "drugs": {
    "ABICIPAR PEGOL": "APPROVAL",
    "AFLIBERCEPT": "APPROVAL",
    "BEVACIZUMAB": "APPROVAL",
    "BEVACIZUMAB GAMMA": "APPROVAL",
    "BEVASIRANIB": "PHASE_3",
    "BROLUCIZUMAB": "APPROVAL",
    "CONBERCEPT": "PHASE_3",
    "FARICIMAB": "APPROVAL",
    "MUPARFOSTAT": "PHASE_3",
    "PEGAPTANIB": "APPROVAL",
    "PEGAPTANIB OCTASODIUM": "PHASE_3",
    "RANIBIZUMAB": "APPROVAL",
    "VANUCIZUMAB": "PHASE_2"
   },
   "approved": [
    "ABICIPAR PEGOL",
    "AFLIBERCEPT",
    "BEVACIZUMAB",
    "BEVACIZUMAB GAMMA",
    "BROLUCIZUMAB",
    "FARICIMAB",
    "PEGAPTANIB",
    "RANIBIZUMAB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ABICIPAR PEGOL": [
     "ocular vascular disorder"
    ],
    "AFLIBERCEPT": [
     "macular degeneration",
     "retinal vein occlusion",
     "colorectal cancer",
     "choroidal neovascularization",
     "diabetic macular edema",
     "myopia",
     "edema",
     "metastatic colorectal cancer",
     "macular retinal edema",
     "macrovascular complications of diabetes",
     "wet macular degeneration",
     "colorectal neoplasm",
     "pathological myopia",
     "diabetic retinopathy",
     "colorectal adenocarcinoma",
     "ocular vascular disorder"
    ],
    "BEVACIZUMAB": [
     "colorectal cancer",
     "non-small cell squamous lung carcinoma",
     "breast cancer",
     "cervical cancer",
     "non-small cell lung carcinoma",
     "colorectal adenocarcinoma",
     "renal cell carcinoma",
     "colonic neoplasm",
     "glioblastoma",
     "metastatic colorectal cancer",
     "breast neoplasm",
     "peritoneal neoplasm",
     "colorectal neoplasm",
     "fallopian tube neoplasm",
     "ovarian neoplasm",
     "fallopian tube carcinoma",
     "ocular vascular disorder"
    ],
    "BEVACIZUMAB GAMMA": [
     "wet macular degeneration"
    ],
    "BROLUCIZUMAB": [
     "macular degeneration",
     "wet macular degeneration",
     "ocular vascular disorder"
    ],
    "FARICIMAB": [
     "diabetic macular edema",
     "wet macular degeneration",
     "macular retinal edema",
     "cystoid macular edema",
     "ocular vascular disorder"
    ],
    "PEGAPTANIB": [
     "wet macular degeneration",
     "macular degeneration"
    ],
    "RANIBIZUMAB": [
     "macular degeneration",
     "hereditary hemorrhagic telangiectasia",
     "macular retinal edema",
     "diabetic retinopathy",
     "wet macular degeneration",
     "macrovascular complications of diabetes",
     "myopia",
     "pathological myopia",
     "choroidal neovascularization",
     "retinal vein occlusion",
     "ocular vascular disorder"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "GPC3",
   "ensembl": "ENSG00000147257",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "CODRITUZUMAB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "GPC3": {
    "n": 69,
    "n_observational": 1,
    "n_active": 41,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03198546",
      "title": "GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04864054",
      "title": "GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05003895",
      "title": "GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05047510",
      "title": "GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2023-08-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155189",
      "title": "A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620706",
      "title": "Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2022-11-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05652920",
      "title": "Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC",
      "status": "RECRUITING",
      "last_update": "2024-04-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926726",
      "title": "GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2023-07-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06198296",
      "title": "Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",
      "status": "RECRUITING",
      "last_update": "2025-11-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06383520",
      "title": "Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-05-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427941",
      "title": "A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06461624",
      "title": "Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06478693",
      "title": "A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC",
      "status": "RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06560827",
      "title": "CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection",
      "status": "RECRUITING",
      "last_update": "2024-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06590246",
      "title": "A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)",
      "status": "RECRUITING",
      "last_update": "2026-01-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06652243",
      "title": "Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06687941",
      "title": "A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06718153",
      "title": "Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726161",
      "title": "Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06795022",
      "title": "First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06891742",
      "title": "Phase I Study of OriC902 in Treatment of Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06902389",
      "title": "A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07039201",
      "title": "A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)",
      "status": "RECRUITING",
      "last_update": "2026-01-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07148050",
      "title": "Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07164313",
      "title": "A Study of ZW251 in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07242417",
      "title": "TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07324304",
      "title": "NWRD06 DNA Plasmid for HCC After Curative Resection.",
      "status": "RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493044",
      "title": "An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07500220",
      "title": "Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523529",
      "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677774",
      "title": "GPC3-Targeted PET/CT in Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07795437",
      "title": "GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00746317",
      "title": "A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)",
      "status": "COMPLETED",
      "last_update": "2012-10-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00976170",
      "title": "Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)",
      "status": "COMPLETED",
      "last_update": "2014-10-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01507168",
      "title": "A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02395250",
      "title": "Anti-GPC3 CAR T for Treating Patients With Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02715362",
      "title": "A Study of GPC3 Redirected Autologous T Cells for Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2016-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02723942",
      "title": "CAR-T Cell Immunotherapy for HCC Targeting GPC3",
      "status": "WITHDRAWN",
      "last_update": "2020-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02905188",
      "title": "Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)",
      "status": "COMPLETED",
      "last_update": "2025-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959151",
      "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
      "status": "UNKNOWN",
      "last_update": "2016-11-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03084380",
      "title": "Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2017-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03130712",
      "title": "A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)",
      "status": "UNKNOWN",
      "last_update": "2017-04-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03146234",
      "title": "CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03175705",
      "title": "Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2018-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03302403",
      "title": "Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-10-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03884751",
      "title": "Chimeric Antigen Receptor T Cells Targeting Glypican-3",
      "status": "COMPLETED",
      "last_update": "2022-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03980288",
      "title": "4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3",
      "status": "COMPLETED",
      "last_update": "2023-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04093648",
      "title": "T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)",
      "status": "WITHDRAWN",
      "last_update": "2020-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04121273",
      "title": "GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2021-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04506983",
      "title": "GPC3-CAR-T Cells for the Hepatocellular Carcinoma",
      "status": "SUSPENDED",
      "last_update": "2022-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04756648",
      "title": "Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04951141",
      "title": "Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors",
      "status": "UNKNOWN",
      "last_update": "2021-07-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04973098",
      "title": "Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05059821",
      "title": "Personalized Cancer Vaccine in Egyptian Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2022-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05070156",
      "title": "B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-12-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05103631",
      "title": "Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05120271",
      "title": "BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05344664",
      "title": "Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05352542",
      "title": "GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05783570",
      "title": "To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307",
      "status": "UNKNOWN",
      "last_update": "2024-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084884",
      "title": "A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06088459",
      "title": "NWRD06 DNA Plasmid for HCC After Radical Resection",
      "status": "UNKNOWN",
      "last_update": "2023-10-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06144385",
      "title": "A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06641453",
      "title": "CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06968195",
      "title": "Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma",
      "status": "SUSPENDED",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07224568",
      "title": "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07352345",
      "title": "Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07487402",
      "title": "Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07590336",
      "title": "68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 39,
     "n_observational": 0,
     "n_active": 20,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT03198546",
       "title": "GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04864054",
       "title": "GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC",
       "status": "RECRUITING",
       "last_update": "2026-06-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05003895",
       "title": "GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-04-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05155189",
       "title": "A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma",
       "status": "RECRUITING",
       "last_update": "2026-01-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05620706",
       "title": "Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma",
       "status": "RECRUITING",
       "last_update": "2022-11-22",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05652920",
       "title": "Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC",
       "status": "RECRUITING",
       "last_update": "2024-04-03",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05926726",
       "title": "GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma",
       "status": "RECRUITING",
       "last_update": "2023-07-03",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06198296",
       "title": "Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",
       "status": "RECRUITING",
       "last_update": "2025-11-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06461624",
       "title": "Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma",
       "status": "RECRUITING",
       "last_update": "2024-11-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06560827",
       "title": "CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection",
       "status": "RECRUITING",
       "last_update": "2024-08-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06902389",
       "title": "A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma",
       "status": "RECRUITING",
       "last_update": "2025-09-03",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07148050",
       "title": "Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",
       "status": "RECRUITING",
       "last_update": "2026-02-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07493044",
       "title": "An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma",
       "status": "RECRUITING",
       "last_update": "2026-05-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07500220",
       "title": "Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC",
       "status": "RECRUITING",
       "last_update": "2026-03-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523529",
       "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02395250",
       "title": "Anti-GPC3 CAR T for Treating Patients With Advanced HCC",
       "status": "COMPLETED",
       "last_update": "2019-08-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02715362",
       "title": "A Study of GPC3 Redirected Autologous T Cells for Advanced HCC",
       "status": "UNKNOWN",
       "last_update": "2016-03-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02723942",
       "title": "CAR-T Cell Immunotherapy for HCC Targeting GPC3",
       "status": "WITHDRAWN",
       "last_update": "2020-07-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02905188",
       "title": "Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)",
       "status": "COMPLETED",
       "last_update": "2025-02-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02959151",
       "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
       "status": "UNKNOWN",
       "last_update": "2016-11-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03084380",
       "title": "Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)",
       "status": "UNKNOWN",
       "last_update": "2017-03-20",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03130712",
       "title": "A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)",
       "status": "UNKNOWN",
       "last_update": "2017-04-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03146234",
       "title": "CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma",
       "status": "COMPLETED",
       "last_update": "2019-08-28",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03175705",
       "title": "Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC",
       "status": "UNKNOWN",
       "last_update": "2018-01-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03302403",
       "title": "Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors",
       "status": "UNKNOWN",
       "last_update": "2020-10-08",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03884751",
       "title": "Chimeric Antigen Receptor T Cells Targeting Glypican-3",
       "status": "COMPLETED",
       "last_update": "2022-02-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03980288",
       "title": "4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3",
       "status": "COMPLETED",
       "last_update": "2023-01-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04093648",
       "title": "T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)",
       "status": "WITHDRAWN",
       "last_update": "2020-05-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04121273",
       "title": "GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC",
       "status": "UNKNOWN",
       "last_update": "2021-03-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04506983",
       "title": "GPC3-CAR-T Cells for the Hepatocellular Carcinoma",
       "status": "SUSPENDED",
       "last_update": "2022-02-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04951141",
       "title": "Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors",
       "status": "UNKNOWN",
       "last_update": "2021-07-06",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05103631",
       "title": "Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-03-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05120271",
       "title": "BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-12-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05344664",
       "title": "Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma",
       "status": "UNKNOWN",
       "last_update": "2022-04-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05352542",
       "title": "GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma",
       "status": "TERMINATED",
       "last_update": "2024-08-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06641453",
       "title": "CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2024-10-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06968195",
       "title": "Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma",
       "status": "SUSPENDED",
       "last_update": "2026-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07224568",
       "title": "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-11-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07487402",
       "title": "Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-04-21",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "GPC3",
     "glypican-3",
     "glypican 3",
     "codrituzumab",
     "GC33"
    ]
   },
   "AFP": {
    "n": 43,
    "n_observational": 42,
    "n_active": 13,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05486572",
      "title": "Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05971108",
      "title": "Real-world Elecsys\u00ae GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC",
      "status": "RECRUITING",
      "last_update": "2025-09-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084234",
      "title": "National Liver Cancer Screening Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06383520",
      "title": "Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-05-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427941",
      "title": "A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06515314",
      "title": "HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059494",
      "title": "Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07469319",
      "title": "Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005629",
      "title": "Vaccine Therapy in Treating Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022334",
      "title": "Vaccine Therapy in Treating Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00093548",
      "title": "Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer",
      "status": "WITHDRAWN",
      "last_update": "2012-10-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00513461",
      "title": "Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection",
      "status": "COMPLETED",
      "last_update": "2018-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00669136",
      "title": "Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-12-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01128803",
      "title": "Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response",
      "status": "TERMINATED",
      "last_update": "2013-11-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01350167",
      "title": "Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease",
      "status": "UNKNOWN",
      "last_update": "2011-05-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01377220",
      "title": "Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2011-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01492127",
      "title": "Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment",
      "status": "UNKNOWN",
      "last_update": "2015-04-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072356",
      "title": "Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-09-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02232490",
      "title": "Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L",
      "status": "UNKNOWN",
      "last_update": "2019-02-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02312817",
      "title": "RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System",
      "status": "COMPLETED",
      "last_update": "2025-07-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02435433",
      "title": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02507882",
      "title": "Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2015-07-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02514434",
      "title": "Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]",
      "status": "UNKNOWN",
      "last_update": "2019-03-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02582918",
      "title": "Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5",
      "status": "COMPLETED",
      "last_update": "2022-09-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02728219",
      "title": "Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion",
      "status": "COMPLETED",
      "last_update": "2016-04-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03132792",
      "title": "AFP\u1d9c\u00b3\u00b3\u00b2T in Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2026-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03172559",
      "title": "Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)",
      "status": "WITHDRAWN",
      "last_update": "2020-08-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03175705",
      "title": "Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2018-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311152",
      "title": "Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03349255",
      "title": "Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888859",
      "title": "ET1402L1-ARTEMIS\u21222 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-03-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03965546",
      "title": "ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-08-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03971747",
      "title": "AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04368182",
      "title": "AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04414956",
      "title": "Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-06-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05304234",
      "title": "Liver Cancer Disparities in American Indian and Alaska Native Persons",
      "status": "UNKNOWN",
      "last_update": "2024-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05764551",
      "title": "The Application of Serum DNA Methylation for Patients With HCC",
      "status": "UNKNOWN",
      "last_update": "2023-03-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06991907",
      "title": "PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010588",
      "title": "Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07298577",
      "title": "Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-04-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07319299",
      "title": "STOP HCC-GAAD-APAC-Thailand",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-01-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07436988",
      "title": "Affordable Made-in-India Microspheres for Liver Cancer Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07675187",
      "title": "HCC Risk and Monitoring in Patients With Type 2 Diabetes",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 6,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT06515314",
       "title": "HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2025-12-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03175705",
       "title": "Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC",
       "status": "UNKNOWN",
       "last_update": "2018-01-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03349255",
       "title": "Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma",
       "status": "TERMINATED",
       "last_update": "2019-07-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03888859",
       "title": "ET1402L1-ARTEMIS\u21222 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma",
       "status": "COMPLETED",
       "last_update": "2021-03-29",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03971747",
       "title": "AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma",
       "status": "UNKNOWN",
       "last_update": "2020-04-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04368182",
       "title": "AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma",
       "status": "UNKNOWN",
       "last_update": "2020-04-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "AFP",
     "alpha-fetoprotein",
     "alpha fetoprotein"
    ]
   },
   "CD147": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00819650",
      "title": "A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection",
      "status": "COMPLETED",
      "last_update": "2016-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00829465",
      "title": "Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-04-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01758679",
      "title": "A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2016-02-17",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03993743",
      "title": "A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2019-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT00819650",
       "title": "A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection",
       "status": "COMPLETED",
       "last_update": "2016-04-01",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00829465",
       "title": "Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma",
       "status": "COMPLETED",
       "last_update": "2016-04-01",
       "phase": "PHASE4",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03993743",
       "title": "A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma",
       "status": "UNKNOWN",
       "last_update": "2019-08-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD147",
     "basigin",
     "BSG",
     "metuximab",
     "HAb18G"
    ]
   },
   "MUC1": {
    "n": 6,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT07523529",
      "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02587689",
      "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2016-12-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02839954",
      "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563170",
      "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine",
      "status": "WITHDRAWN",
      "last_update": "2021-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03652077",
      "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05975645",
      "title": "A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).",
      "status": "TERMINATED",
      "last_update": "2025-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07523529",
       "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02587689",
       "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2016-12-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02839954",
       "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2016-12-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "MUC1",
     "mucin-1",
     "mucin 1"
    ]
   },
   "EpCAM": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03013712",
      "title": "A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05028933",
      "title": "IMC001 for Clinical Research on Advanced Digestive System Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06789224",
      "title": "Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03013712",
       "title": "A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer",
       "status": "UNKNOWN",
       "last_update": "2017-01-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "EpCAM",
     "EPCAM",
     "epithelial cell adhesion molecule"
    ]
   }
  },
  "by_drug": {
   "AFLIBERCEPT": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00082823",
      "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00083213",
      "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159989",
      "title": "Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2025-10-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AMIVANTAMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05653427",
      "title": "A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AXITINIB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01210495",
      "title": "Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01273662",
      "title": "Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01334112",
      "title": "Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01352728",
      "title": "Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib",
      "status": "COMPLETED",
      "last_update": "2018-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02814461",
      "title": "The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC",
      "status": "COMPLETED",
      "last_update": "2019-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03289533",
      "title": "A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)",
      "status": "COMPLETED",
      "last_update": "2020-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249569",
      "title": "Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BEVACIZUMAB": {
    "n": 169,
    "n_observational": 31,
    "n_active": 101,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT03942328",
      "title": "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05185505",
      "title": "Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria",
      "status": "RECRUITING",
      "last_update": "2023-02-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05377034",
      "title": "Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468359",
      "title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05488522",
      "title": "SBRT With Atezo/Bev for HCC",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05528952",
      "title": "Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620771",
      "title": "Therasphere\u00ae and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05690048",
      "title": "Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05733598",
      "title": "Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05751343",
      "title": "Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05919264",
      "title": "FOG-001 in Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05984511",
      "title": "TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT",
      "status": "RECRUITING",
      "last_update": "2025-02-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985798",
      "title": "Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2023-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05992220",
      "title": "Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion",
      "status": "RECRUITING",
      "last_update": "2025-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06031285",
      "title": "Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084481",
      "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06109272",
      "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06254248",
      "title": "Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265350",
      "title": "Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases",
      "status": "RECRUITING",
      "last_update": "2024-02-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06294548",
      "title": "A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06349980",
      "title": "A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.",
      "status": "RECRUITING",
      "last_update": "2024-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06360042",
      "title": "Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC",
      "status": "RECRUITING",
      "last_update": "2024-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06397222",
      "title": "Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC",
      "status": "RECRUITING",
      "last_update": "2024-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06422403",
      "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers",
      "status": "RECRUITING",
      "last_update": "2025-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427941",
      "title": "A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06478693",
      "title": "A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC",
      "status": "RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482801",
      "title": "Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT",
      "status": "RECRUITING",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530251",
      "title": "A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558227",
      "title": "Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06609863",
      "title": "dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-12-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06618664",
      "title": "A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06695026",
      "title": "A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06725121",
      "title": "Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant",
      "status": "RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06737913",
      "title": "HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06789757",
      "title": "The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)",
      "status": "RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06893887",
      "title": "Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-07-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06921785",
      "title": "Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06961526",
      "title": "Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06986785",
      "title": "A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06995105",
      "title": "Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012798",
      "title": "FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07018947",
      "title": "Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07047586",
      "title": "Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059494",
      "title": "Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07062055",
      "title": "BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07157969",
      "title": "ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2025-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166406",
      "title": "Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179900",
      "title": "Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192185",
      "title": "Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07239245",
      "title": "Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo",
      "status": "RECRUITING",
      "last_update": "2025-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07246668",
      "title": "A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07293468",
      "title": "Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)",
      "status": "RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07317414",
      "title": "\u03b2-alanine in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07324824",
      "title": "Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07422753",
      "title": "A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07478302",
      "title": "A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07479485",
      "title": "MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07490262",
      "title": "A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07501351",
      "title": "Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07557251",
      "title": "A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049322",
      "title": "Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery",
      "status": "COMPLETED",
      "last_update": "2020-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055692",
      "title": "Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2016-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00142467",
      "title": "Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00280007",
      "title": "Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2010-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00287222",
      "title": "Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00365391",
      "title": "Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2015-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410956",
      "title": "Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2024-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00426829",
      "title": "Proton Therapy and Bevacizumab for Primary Liver Tumors",
      "status": "TERMINATED",
      "last_update": "2012-08-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00576199",
      "title": "A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2014-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00775073",
      "title": "Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001",
      "status": "COMPLETED",
      "last_update": "2012-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00881751",
      "title": "Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2017-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01180959",
      "title": "Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519348",
      "title": "A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03778957",
      "title": "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03847428",
      "title": "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03937830",
      "title": "Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04102098",
      "title": "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04135690",
      "title": "HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial",
      "status": "UNKNOWN",
      "last_update": "2023-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04170556",
      "title": "Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)",
      "status": "COMPLETED",
      "last_update": "2024-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04180072",
      "title": "Atezolizumab Plus Bevacizumab With HCC and HBV Infection",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04224636",
      "title": "Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab",
      "status": "UNKNOWN",
      "last_update": "2024-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04487067",
      "title": "A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista",
      "status": "COMPLETED",
      "last_update": "2025-09-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04592029",
      "title": "TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599777",
      "title": "TACE Combined With Sorafenib and Tislelizumab for Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2022-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605796",
      "title": "A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04649489",
      "title": "A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04712643",
      "title": "A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04723004",
      "title": "Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC",
      "status": "COMPLETED",
      "last_update": "2026-07-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04732286",
      "title": "A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04796025",
      "title": "TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study",
      "status": "UNKNOWN",
      "last_update": "2021-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04829383",
      "title": "A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04843943",
      "title": "Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC",
      "status": "UNKNOWN",
      "last_update": "2021-04-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04857684",
      "title": "SBRT + Atezolizumab + Bevacizumab in Resectable HCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-01",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04948697",
      "title": "A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2025-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007106",
      "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05022927",
      "title": "A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05029973",
      "title": "HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC",
      "status": "UNKNOWN",
      "last_update": "2023-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05075993",
      "title": "Study of LVGN3616 and LVGN6051\u00b1LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097911",
      "title": "Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05101629",
      "title": "Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy",
      "status": "COMPLETED",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05104567",
      "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)",
      "status": "COMPLETED",
      "last_update": "2025-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05109052",
      "title": "Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2023-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05134532",
      "title": "Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2023-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05137899",
      "title": "Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy",
      "status": "TERMINATED",
      "last_update": "2025-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211323",
      "title": "A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249426",
      "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05277675",
      "title": "Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)",
      "status": "UNKNOWN",
      "last_update": "2022-03-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05337137",
      "title": "A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05359861",
      "title": "Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05363722",
      "title": "A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05396937",
      "title": "Efficacy and Safety of T+A+RAD in HCC",
      "status": "UNKNOWN",
      "last_update": "2022-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05441475",
      "title": "A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05448677",
      "title": "Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05530785",
      "title": "Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT",
      "status": "UNKNOWN",
      "last_update": "2022-09-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05546879",
      "title": "Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05603039",
      "title": "A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05616390",
      "title": "Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05617430",
      "title": "Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05625893",
      "title": "Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion",
      "status": "COMPLETED",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665348",
      "title": "Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05705791",
      "title": "Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-07-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05750030",
      "title": "FMT in IT-refractory HCC - FAB-HCC Pilot Study",
      "status": "COMPLETED",
      "last_update": "2025-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05760430",
      "title": "The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05775159",
      "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864755",
      "title": "HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05883176",
      "title": "TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria",
      "status": "UNKNOWN",
      "last_update": "2023-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05886257",
      "title": "Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T",
      "status": "WITHDRAWN",
      "last_update": "2023-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05904886",
      "title": "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05908786",
      "title": "A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05908916",
      "title": "Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05975463",
      "title": "Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy",
      "status": "UNKNOWN",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05976568",
      "title": "A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-08-04",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006286",
      "title": "A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2024-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06040099",
      "title": "A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06090656",
      "title": "Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)",
      "status": "UNKNOWN",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06096779",
      "title": "A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06138769",
      "title": "Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06233994",
      "title": "A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285019",
      "title": "Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06370065",
      "title": "Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients",
      "status": "UNKNOWN",
      "last_update": "2024-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06405061",
      "title": "Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma",
      "status": "SUSPENDED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530784",
      "title": "Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06592612",
      "title": "Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06679985",
      "title": "A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06680258",
      "title": "A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06958484",
      "title": "Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06984718",
      "title": "A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07009470",
      "title": "A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07075562",
      "title": "TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion",
      "status": "COMPLETED",
      "last_update": "2025-07-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07109336",
      "title": "Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-09-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07128251",
      "title": "A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07272265",
      "title": "The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study",
      "status": "COMPLETED",
      "last_update": "2025-12-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07281664",
      "title": "Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07328802",
      "title": "Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07351513",
      "title": "A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07363356",
      "title": "Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07392866",
      "title": "A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07522411",
      "title": "Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07537985",
      "title": "Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07543510",
      "title": "Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07627191",
      "title": "GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691762",
      "title": "A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714317",
      "title": "Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07761286",
      "title": "Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07774247",
      "title": "Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BEVACIZUMAB GAMMA": {
    "n": 5,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03942328",
      "title": "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166406",
      "title": "Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01010126",
      "title": "Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04721132",
      "title": "Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211323",
      "title": "A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BRIVANIB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00355238",
      "title": "A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer",
      "status": "COMPLETED",
      "last_update": "2023-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00437424",
      "title": "A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2011-05-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00825955",
      "title": "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment",
      "status": "COMPLETED",
      "last_update": "2019-10-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00858871",
      "title": "First Line Hepato Cellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2016-10-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00908752",
      "title": "Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC",
      "status": "COMPLETED",
      "last_update": "2019-12-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108705",
      "title": "Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment",
      "status": "TERMINATED",
      "last_update": "2015-10-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01540461",
      "title": "Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)",
      "status": "COMPLETED",
      "last_update": "2014-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516071",
      "title": "A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04212221",
      "title": "MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2024-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BRIVANIB ALANINATE": {
    "n": 9,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00355238",
      "title": "A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer",
      "status": "COMPLETED",
      "last_update": "2023-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00437424",
      "title": "A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2011-05-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00825955",
      "title": "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment",
      "status": "COMPLETED",
      "last_update": "2019-10-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00858871",
      "title": "First Line Hepato Cellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2016-10-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00908752",
      "title": "Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC",
      "status": "COMPLETED",
      "last_update": "2019-12-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108705",
      "title": "Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment",
      "status": "TERMINATED",
      "last_update": "2015-10-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01540461",
      "title": "Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)",
      "status": "COMPLETED",
      "last_update": "2014-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516071",
      "title": "A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04212221",
      "title": "MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2024-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB": {
    "n": 34,
    "n_observational": 1,
    "n_active": 18,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03539822",
      "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03899428",
      "title": "Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC",
      "status": "RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04204850",
      "title": "Cabozantinib to Treat Recurrent Liver Cancer Post Transplant",
      "status": "RECRUITING",
      "last_update": "2025-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04472767",
      "title": "Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05168163",
      "title": "Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05443087",
      "title": "TARGETed Therapy Drug MONITOring in DIGestive Oncology",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05797805",
      "title": "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-07-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06698250",
      "title": "Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)",
      "status": "RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06811116",
      "title": "Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein \u03b2-Catenin, The SAPHIRE Trial",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940225",
      "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01658878",
      "title": "An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2025-12-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01908426",
      "title": "Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib",
      "status": "COMPLETED",
      "last_update": "2021-05-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03299946",
      "title": "Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2024-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03586973",
      "title": "A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03755791",
      "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03963206",
      "title": "Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)",
      "status": "COMPLETED",
      "last_update": "2025-12-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04316182",
      "title": "Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04435977",
      "title": "Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04442581",
      "title": "Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04454762",
      "title": "A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function",
      "status": "UNKNOWN",
      "last_update": "2020-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04497038",
      "title": "Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy",
      "status": "TERMINATED",
      "last_update": "2024-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511455",
      "title": "Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment",
      "status": "COMPLETED",
      "last_update": "2025-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522908",
      "title": "Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function",
      "status": "COMPLETED",
      "last_update": "2025-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04588051",
      "title": "Cabozantinib in Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04767906",
      "title": "Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05039736",
      "title": "A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy",
      "status": "WITHDRAWN",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327738",
      "title": "Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-12-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06535737",
      "title": "A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07151326",
      "title": "Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB S-MALATE": {
    "n": 6,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06811116",
      "title": "Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein \u03b2-Catenin, The SAPHIRE Trial",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04442581",
      "title": "Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327738",
      "title": "Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-12-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CAPMATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01324479",
      "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01737827",
      "title": "Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.",
      "status": "TERMINATED",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01964235",
      "title": "Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2016-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02795429",
      "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2023-07-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CATEQUENTINIB": {
    "n": 26,
    "n_observational": 3,
    "n_active": 5,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05862337",
      "title": "Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.",
      "status": "RECRUITING",
      "last_update": "2023-05-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02809534",
      "title": "A Study of Anlotinib in Patients With Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03766776",
      "title": "Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2018-12-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03825705",
      "title": "A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2019-10-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03945799",
      "title": "A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence",
      "status": "TERMINATED",
      "last_update": "2022-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03950518",
      "title": "Novel Treatment of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2019-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04052152",
      "title": "Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2019-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04066543",
      "title": "TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients",
      "status": "UNKNOWN",
      "last_update": "2019-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04080154",
      "title": "Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157140",
      "title": "Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2019-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172571",
      "title": "A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2024-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04213118",
      "title": "Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence",
      "status": "UNKNOWN",
      "last_update": "2023-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04344158",
      "title": "A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665609",
      "title": "Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC",
      "status": "UNKNOWN",
      "last_update": "2021-03-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04888546",
      "title": "TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis",
      "status": "UNKNOWN",
      "last_update": "2021-05-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04947371",
      "title": "Adjuvant Therapy With Anlotinib for HCC",
      "status": "WITHDRAWN",
      "last_update": "2021-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05111366",
      "title": "TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection",
      "status": "UNKNOWN",
      "last_update": "2022-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311319",
      "title": "HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection",
      "status": "UNKNOWN",
      "last_update": "2022-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05344924",
      "title": "TACE Combined With Penpulimab and Anlotinib for Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2022-12-29",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453383",
      "title": "Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib",
      "status": "UNKNOWN",
      "last_update": "2022-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05975645",
      "title": "A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).",
      "status": "TERMINATED",
      "last_update": "2025-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06031480",
      "title": "Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors",
      "status": "UNKNOWN",
      "last_update": "2023-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06475287",
      "title": "HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07363512",
      "title": "Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07537777",
      "title": "Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07746960",
      "title": "Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEDIRANIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00238394",
      "title": "Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00427973",
      "title": "AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2016-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01229111",
      "title": "Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers",
      "status": "TERMINATED",
      "last_update": "2017-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CODRITUZUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00746317",
      "title": "A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)",
      "status": "COMPLETED",
      "last_update": "2012-10-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00976170",
      "title": "Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)",
      "status": "COMPLETED",
      "last_update": "2014-10-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01507168",
      "title": "A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CONTUSUGENE LADENOVEC": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00003147",
      "title": "Gene Therapy in Treating Patients With Cancer of The Liver",
      "status": "TERMINATED",
      "last_update": "2013-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CRIZOTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DERAZANTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03230318",
      "title": "Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2023-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOVITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01232296",
      "title": "A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment",
      "status": "COMPLETED",
      "last_update": "2015-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EMIBETUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02082210",
      "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENMD-2076": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02234986",
      "title": "A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ERDAFITINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02421185",
      "title": "Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-02-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FEXAGRATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FGF401": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02325739",
      "title": "FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression",
      "status": "COMPLETED",
      "last_update": "2024-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FORETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00920192",
      "title": "Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FRUQUINTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06446154",
      "title": "Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05971199",
      "title": "Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FUTIBATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04828486",
      "title": "Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LENVATINIB": {
    "n": 168,
    "n_observational": 32,
    "n_active": 81,
    "n_withdrawn": 7,
    "trials": [
     {
      "nct": "NCT03899428",
      "title": "Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC",
      "status": "RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04615143",
      "title": "Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC",
      "status": "RECRUITING",
      "last_update": "2025-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04803318",
      "title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05057845",
      "title": "Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155189",
      "title": "A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05185739",
      "title": "Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)",
      "status": "RECRUITING",
      "last_update": "2024-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05444478",
      "title": "Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2023-11-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608200",
      "title": "Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2023-05-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608213",
      "title": "Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC",
      "status": "RECRUITING",
      "last_update": "2022-11-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05738616",
      "title": "Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)",
      "status": "RECRUITING",
      "last_update": "2024-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05797805",
      "title": "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-07-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05920863",
      "title": "Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors",
      "status": "RECRUITING",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05954897",
      "title": "Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2023-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985798",
      "title": "Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2023-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041477",
      "title": "Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC",
      "status": "RECRUITING",
      "last_update": "2024-08-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06061276",
      "title": "bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC",
      "status": "RECRUITING",
      "last_update": "2024-09-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06201065",
      "title": "FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial",
      "status": "RECRUITING",
      "last_update": "2024-01-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06215651",
      "title": "Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06261125",
      "title": "Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)",
      "status": "RECRUITING",
      "last_update": "2024-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06363006",
      "title": "Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer",
      "status": "RECRUITING",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06371157",
      "title": "A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06389422",
      "title": "Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis",
      "status": "RECRUITING",
      "last_update": "2024-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06406634",
      "title": "Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06492395",
      "title": "Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT",
      "status": "RECRUITING",
      "last_update": "2025-01-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06550921",
      "title": "Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06609863",
      "title": "dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-12-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06622031",
      "title": "TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT",
      "status": "RECRUITING",
      "last_update": "2025-01-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06740370",
      "title": "TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06858813",
      "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880523",
      "title": "STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06904014",
      "title": "Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC",
      "status": "RECRUITING",
      "last_update": "2025-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06904183",
      "title": "Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06986785",
      "title": "A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07014150",
      "title": "Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07047586",
      "title": "Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07157969",
      "title": "ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2025-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07219459",
      "title": "Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07408804",
      "title": "Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07482059",
      "title": "A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493668",
      "title": "Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07501351",
      "title": "Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07801287",
      "title": "Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00946153",
      "title": "Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2019-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01761266",
      "title": "A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-04-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02953743",
      "title": "Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2021-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418922",
      "title": "A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-06-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03433703",
      "title": "Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)",
      "status": "TERMINATED",
      "last_update": "2019-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03499626",
      "title": "Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2018-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03746249",
      "title": "Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC",
      "status": "WITHDRAWN",
      "last_update": "2019-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03775395",
      "title": "HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2019-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03775707",
      "title": "Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria",
      "status": "WITHDRAWN",
      "last_update": "2019-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03781934",
      "title": "A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations",
      "status": "COMPLETED",
      "last_update": "2025-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03791918",
      "title": "Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria",
      "status": "WITHDRAWN",
      "last_update": "2019-05-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03838796",
      "title": "Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841201",
      "title": "Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03867370",
      "title": "Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03905967",
      "title": "TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2019-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919383",
      "title": "Phase II of Lenvatinib Plus Toripalimab for Advanced HCC",
      "status": "WITHDRAWN",
      "last_update": "2019-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04008797",
      "title": "A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04039607",
      "title": "A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04042805",
      "title": "Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044313",
      "title": "HAIC Plus Lenvatinib and Toripalimab for Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2023-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044651",
      "title": "Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection",
      "status": "WITHDRAWN",
      "last_update": "2020-01-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04053972",
      "title": "The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.",
      "status": "UNKNOWN",
      "last_update": "2019-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04053985",
      "title": "The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2019-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04080154",
      "title": "Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04168944",
      "title": "Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2019-11-19",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04170179",
      "title": "Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis",
      "status": "UNKNOWN",
      "last_update": "2021-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04194775",
      "title": "A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04227808",
      "title": "Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04229355",
      "title": "DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04237740",
      "title": "Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation",
      "status": "UNKNOWN",
      "last_update": "2020-03-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04246177",
      "title": "Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)",
      "status": "TERMINATED",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04297254",
      "title": "A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC",
      "status": "COMPLETED",
      "last_update": "2023-11-15",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04317248",
      "title": "\"Cocktail\" Therapy for Hepatitis B Related Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04319484",
      "title": "Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus",
      "status": "UNKNOWN",
      "last_update": "2020-03-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04368078",
      "title": "Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04401800",
      "title": "Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04443309",
      "title": "Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04443322",
      "title": "Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )",
      "status": "UNKNOWN",
      "last_update": "2020-09-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04444167",
      "title": "A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04490694",
      "title": "TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04523493",
      "title": "Phase III Study of Toripalimab\uff08JS001\uff09 Combined With Lenvatinib for Advanced HCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04531228",
      "title": "TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial",
      "status": "UNKNOWN",
      "last_update": "2021-09-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599790",
      "title": "TACE Combined With Lenvatinib and Sintilimab for Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2022-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605796",
      "title": "A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04618367",
      "title": "HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT",
      "status": "COMPLETED",
      "last_update": "2024-03-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04728321",
      "title": "A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04791176",
      "title": "Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04814043",
      "title": "PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial",
      "status": "UNKNOWN",
      "last_update": "2021-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04909866",
      "title": "The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study",
      "status": "UNKNOWN",
      "last_update": "2021-06-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04911959",
      "title": "Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC",
      "status": "UNKNOWN",
      "last_update": "2023-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04961918",
      "title": "The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2021-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974281",
      "title": "PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC",
      "status": "UNKNOWN",
      "last_update": "2022-08-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007106",
      "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007587",
      "title": "Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2021-08-16",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05033522",
      "title": "Immunotherapy for Advanced Liver Cancer",
      "status": "SUSPENDED",
      "last_update": "2025-10-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05042336",
      "title": "The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC",
      "status": "UNKNOWN",
      "last_update": "2021-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05056337",
      "title": "Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC",
      "status": "UNKNOWN",
      "last_update": "2021-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091346",
      "title": "A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05101629",
      "title": "Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy",
      "status": "COMPLETED",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05103904",
      "title": "Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant",
      "status": "TERMINATED",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05113186",
      "title": "Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131698",
      "title": "Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-01-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135364",
      "title": "HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure",
      "status": "UNKNOWN",
      "last_update": "2021-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05162898",
      "title": "Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.",
      "status": "UNKNOWN",
      "last_update": "2022-01-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05166239",
      "title": "HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT",
      "status": "COMPLETED",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05171335",
      "title": "Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2022-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05213221",
      "title": "Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients",
      "status": "COMPLETED",
      "last_update": "2023-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05220020",
      "title": "TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-05-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05277675",
      "title": "Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)",
      "status": "UNKNOWN",
      "last_update": "2022-03-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05286320",
      "title": "Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05290220",
      "title": "HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05301842",
      "title": "Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05312216",
      "title": "Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05319431",
      "title": "A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05391867",
      "title": "Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-05-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05408221",
      "title": "the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582109",
      "title": "Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582278",
      "title": "HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC",
      "status": "UNKNOWN",
      "last_update": "2022-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05592197",
      "title": "Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT",
      "status": "WITHDRAWN",
      "last_update": "2023-02-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05621499",
      "title": "HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05675462",
      "title": "Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05718232",
      "title": "SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05718882",
      "title": "Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05775159",
      "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05803928",
      "title": "Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies",
      "status": "UNKNOWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05807776",
      "title": "Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.",
      "status": "COMPLETED",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05822752",
      "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05842317",
      "title": "Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC",
      "status": "UNKNOWN",
      "last_update": "2024-02-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05897138",
      "title": "A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05897268",
      "title": "Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)",
      "status": "UNKNOWN",
      "last_update": "2023-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05903456",
      "title": "Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05910970",
      "title": "Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation",
      "status": "UNKNOWN",
      "last_update": "2024-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05992584",
      "title": "Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC",
      "status": "UNKNOWN",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034977",
      "title": "Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-09-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06070636",
      "title": "bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06089382",
      "title": "A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06138769",
      "title": "Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06143579",
      "title": "A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06233981",
      "title": "Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253598",
      "title": "Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06311916",
      "title": "Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-15",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06361758",
      "title": "Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC",
      "status": "WITHDRAWN",
      "last_update": "2025-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364007",
      "title": "HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC",
      "status": "UNKNOWN",
      "last_update": "2024-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06409637",
      "title": "FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06519721",
      "title": "Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06592612",
      "title": "Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708650",
      "title": "Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06884982",
      "title": "An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06984718",
      "title": "A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07131501",
      "title": "A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07150377",
      "title": "A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07184424",
      "title": "Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2025-09-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07297654",
      "title": "First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07350070",
      "title": "TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07351513",
      "title": "A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480382",
      "title": "Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07487662",
      "title": "TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07514429",
      "title": "Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07518706",
      "title": "Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07535840",
      "title": "A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07537946",
      "title": "Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07537985",
      "title": "Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07540832",
      "title": "Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07776080",
      "title": "Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07790419",
      "title": "A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LINIFANIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00517920",
      "title": "Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2013-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01009593",
      "title": "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2012-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LUCITANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03260179",
      "title": "Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810",
      "status": "UNKNOWN",
      "last_update": "2017-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MUPARFOSTAT": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01402908",
      "title": "A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection",
      "status": "TERMINATED",
      "last_update": "2022-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NINGETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04601610",
      "title": "KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NINTEDANIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00987935",
      "title": "A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01004003",
      "title": "Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01594125",
      "title": "Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NINTEDANIB ESYLATE": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00987935",
      "title": "A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01004003",
      "title": "Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01594125",
      "title": "Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ONARTUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01897038",
      "title": "A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ORANTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00784290",
      "title": "Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01465464",
      "title": "Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-08-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PAZOPANIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00370513",
      "title": "A Phase I Study of Pazopanib in Adult Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01012362",
      "title": "Study of Pazopanib and Ixabepilone in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RAMUCIRUMAB": {
    "n": 12,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04770207",
      "title": "Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs",
      "status": "RECRUITING",
      "last_update": "2024-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00627042",
      "title": "Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2014-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01140347",
      "title": "A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib",
      "status": "COMPLETED",
      "last_update": "2015-12-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01246986",
      "title": "A Study of LY2157299 in Participants With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-01-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02069041",
      "title": "A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02082210",
      "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02435433",
      "title": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02520141",
      "title": "Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02572687",
      "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-01-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05856864",
      "title": "Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy",
      "status": "UNKNOWN",
      "last_update": "2024-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06441019",
      "title": "Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691645",
      "title": "Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 52,
    "n_observational": 13,
    "n_active": 26,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03899428",
      "title": "Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC",
      "status": "RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155189",
      "title": "A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05443087",
      "title": "TARGETed Therapy Drug MONITOring in DIGestive Oncology",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05917431",
      "title": "Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC",
      "status": "RECRUITING",
      "last_update": "2023-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06280105",
      "title": "A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib",
      "status": "RECRUITING",
      "last_update": "2025-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06363006",
      "title": "Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer",
      "status": "RECRUITING",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06841172",
      "title": "Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC",
      "status": "RECRUITING",
      "last_update": "2025-08-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07100392",
      "title": "Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07310173",
      "title": "Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07328009",
      "title": "A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07463248",
      "title": "PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07501351",
      "title": "Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01003015",
      "title": "Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01774344",
      "title": "Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03347292",
      "title": "Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC",
      "status": "COMPLETED",
      "last_update": "2023-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475953",
      "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03890731",
      "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed",
      "status": "COMPLETED",
      "last_update": "2024-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03956940",
      "title": "Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib",
      "status": "TERMINATED",
      "last_update": "2022-06-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04170556",
      "title": "Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)",
      "status": "COMPLETED",
      "last_update": "2024-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04183088",
      "title": "Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04310709",
      "title": "Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04327700",
      "title": "Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib",
      "status": "TERMINATED",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04476329",
      "title": "Optimization for Regorafenib in HCC",
      "status": "TERMINATED",
      "last_update": "2021-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04696055",
      "title": "Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04718909",
      "title": "Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC",
      "status": "UNKNOWN",
      "last_update": "2022-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04777851",
      "title": "Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04806243",
      "title": "Carelizumab Combined With Regorafenib in the Treatment of HCC\uff08CARE-2020\uff09",
      "status": "UNKNOWN",
      "last_update": "2021-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04985136",
      "title": "A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2022-09-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05048017",
      "title": "Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05134532",
      "title": "Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2023-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135364",
      "title": "HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure",
      "status": "UNKNOWN",
      "last_update": "2021-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05194293",
      "title": "Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05233358",
      "title": "HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure",
      "status": "UNKNOWN",
      "last_update": "2022-02-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05622136",
      "title": "Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05644379",
      "title": "A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05770882",
      "title": "Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2025-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05773105",
      "title": "A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05962450",
      "title": "Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy",
      "status": "UNKNOWN",
      "last_update": "2024-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06375317",
      "title": "HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06592612",
      "title": "Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06856590",
      "title": "ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction",
      "status": "COMPLETED",
      "last_update": "2025-09-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06902246",
      "title": "Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07078305",
      "title": "Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07115550",
      "title": "A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07300488",
      "title": "Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07392866",
      "title": "A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07495579",
      "title": "Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07514429",
      "title": "Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07514455",
      "title": "Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07537985",
      "title": "Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691645",
      "title": "Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RIVOCERANIB": {
    "n": 7,
    "n_observational": 2,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06796803",
      "title": "Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)",
      "status": "RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03764293",
      "title": "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2024-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04639180",
      "title": "A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04985136",
      "title": "A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2022-09-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05320692",
      "title": "A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05367687",
      "title": "A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation",
      "status": "COMPLETED",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07684040",
      "title": "A Study of Combination Therapy in Patients With Resectable Liver Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 175,
    "n_observational": 25,
    "n_active": 11,
    "n_withdrawn": 11,
    "trials": [
     {
      "nct": "NCT03899428",
      "title": "Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC",
      "status": "RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468359",
      "title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06309485",
      "title": "Phase 2 Study of WGI-0301 for Advanced HCC",
      "status": "RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06363006",
      "title": "Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer",
      "status": "RECRUITING",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00044512",
      "title": "A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00105443",
      "title": "A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398814",
      "title": "Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00464919",
      "title": "Sorafenib Plus Tegafur/Uracil (UFUR\u00ae) for Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2009-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478374",
      "title": "Sorafenib With TACE to Treat Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00490685",
      "title": "Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2010-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00494299",
      "title": "Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)",
      "status": "COMPLETED",
      "last_update": "2013-12-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00618384",
      "title": "TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2012-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00619541",
      "title": "Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2009-02-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00687596",
      "title": "Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00703365",
      "title": "Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2011-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00813293",
      "title": "Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00825955",
      "title": "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment",
      "status": "COMPLETED",
      "last_update": "2019-10-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00827177",
      "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00828594",
      "title": "Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2013-04-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00844688",
      "title": "Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2009-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00844883",
      "title": "Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-11-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00872014",
      "title": "A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer",
      "status": "COMPLETED",
      "last_update": "2016-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00873002",
      "title": "Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2012-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00875615",
      "title": "Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2017-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00881751",
      "title": "Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2017-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00901901",
      "title": "Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-05-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00906373",
      "title": "A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00933816",
      "title": "Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2010-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00941967",
      "title": "Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2019-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00949182",
      "title": "Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2014-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00976170",
      "title": "Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)",
      "status": "COMPLETED",
      "last_update": "2014-10-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00987935",
      "title": "A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00999843",
      "title": "Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer",
      "status": "UNKNOWN",
      "last_update": "2009-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01004978",
      "title": "Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2024-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01009593",
      "title": "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2012-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01011010",
      "title": "Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2018-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01029418",
      "title": "AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01035229",
      "title": "Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.",
      "status": "COMPLETED",
      "last_update": "2016-09-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01098760",
      "title": "Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients",
      "status": "COMPLETED",
      "last_update": "2013-10-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101906",
      "title": "A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC",
      "status": "TERMINATED",
      "last_update": "2024-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108705",
      "title": "Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment",
      "status": "TERMINATED",
      "last_update": "2015-10-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01126645",
      "title": "Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131689",
      "title": "Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01157013",
      "title": "Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-07-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01170104",
      "title": "Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2011-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01171651",
      "title": "A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01178411",
      "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01180959",
      "title": "Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01214343",
      "title": "Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2011-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01217034",
      "title": "Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib",
      "status": "UNKNOWN",
      "last_update": "2017-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01232296",
      "title": "A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment",
      "status": "COMPLETED",
      "last_update": "2015-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01245582",
      "title": "Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients",
      "status": "WITHDRAWN",
      "last_update": "2011-11-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01258608",
      "title": "Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01264705",
      "title": "Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2020-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01271504",
      "title": "E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01306058",
      "title": "Sorafenib and TRC105 in Hepatocellular Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01308723",
      "title": "A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01324076",
      "title": "Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",
      "status": "UNKNOWN",
      "last_update": "2011-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01348503",
      "title": "Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01375569",
      "title": "TRC105 for Liver Cancer That Has Not Responded to Sorafenib",
      "status": "COMPLETED",
      "last_update": "2017-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01405573",
      "title": "Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2017-03-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01418729",
      "title": "Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma",
      "status": "COMPLETED",
      "last_update": "2017-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01480817",
      "title": "Sorafenib VS TACE in HCC Patients With Portal Vein Invasion",
      "status": "TERMINATED",
      "last_update": "2016-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01482442",
      "title": "SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497444",
      "title": "Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2020-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01498952",
      "title": "MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.",
      "status": "COMPLETED",
      "last_update": "2019-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01507064",
      "title": "Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01539018",
      "title": "Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE",
      "status": "TERMINATED",
      "last_update": "2015-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01556815",
      "title": "Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2012-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01605734",
      "title": "TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2012-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01624285",
      "title": "Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2023-12-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01628640",
      "title": "Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01655693",
      "title": "Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01666756",
      "title": "Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2021-01-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01687673",
      "title": "Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01747642",
      "title": "Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2012-12-12",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01754987",
      "title": "A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective",
      "status": "COMPLETED",
      "last_update": "2025-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01774344",
      "title": "Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01775501",
      "title": "Sorafenib + mFOLFOX for Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01777594",
      "title": "Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801163",
      "title": "A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)",
      "status": "WITHDRAWN",
      "last_update": "2015-04-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01833299",
      "title": "Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-02-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01840592",
      "title": "Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01849588",
      "title": "HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2017-04-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01897610",
      "title": "Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2023-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01900002",
      "title": "Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2021-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01903694",
      "title": "Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01906216",
      "title": "Sorafenib Chemoembolization Evaluation Controlled Trial",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01908426",
      "title": "Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib",
      "status": "COMPLETED",
      "last_update": "2021-05-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01911273",
      "title": "A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01915602",
      "title": "Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2021-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01953406",
      "title": "The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2016-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01964235",
      "title": "Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2016-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01988493",
      "title": "Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02029157",
      "title": "A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072486",
      "title": "Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-07-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02129322",
      "title": "Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1",
      "status": "WITHDRAWN",
      "last_update": "2021-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02178358",
      "title": "A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02227914",
      "title": "Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2017-05-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02259647",
      "title": "Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-10-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02279719",
      "title": "A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-11-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02288507",
      "title": "Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer",
      "status": "WITHDRAWN",
      "last_update": "2019-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02323906",
      "title": "Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2017-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02354898",
      "title": "A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406508",
      "title": "Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC",
      "status": "WITHDRAWN",
      "last_update": "2017-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02435433",
      "title": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02504983",
      "title": "Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-02-05",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02575339",
      "title": "MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-07-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576509",
      "title": "An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02642913",
      "title": "Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02716012",
      "title": "First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer",
      "status": "UNKNOWN",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02716766",
      "title": "Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2020-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02733809",
      "title": "Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2019-08-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02748304",
      "title": "Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-02-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02794337",
      "title": "TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-04-27",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02856126",
      "title": "HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2024-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867280",
      "title": "Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection",
      "status": "TERMINATED",
      "last_update": "2020-02-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02908165",
      "title": "Randomized Phase II Trial of Chemoembolization and Sorafenib",
      "status": "WITHDRAWN",
      "last_update": "2018-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02961998",
      "title": "Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail",
      "status": "COMPLETED",
      "last_update": "2019-09-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02971696",
      "title": "Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.",
      "status": "COMPLETED",
      "last_update": "2018-06-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981498",
      "title": "Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02988440",
      "title": "Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03008512",
      "title": "A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib",
      "status": "TERMINATED",
      "last_update": "2021-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097848",
      "title": "Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2017-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03140332",
      "title": "Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.",
      "status": "COMPLETED",
      "last_update": "2020-07-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03211416",
      "title": "Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212625",
      "title": "The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction",
      "status": "COMPLETED",
      "last_update": "2019-08-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236649",
      "title": "The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects",
      "status": "TERMINATED",
      "last_update": "2023-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03275376",
      "title": "Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03298451",
      "title": "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03499626",
      "title": "Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)",
      "status": "UNKNOWN",
      "last_update": "2018-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03511703",
      "title": "The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2018-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516071",
      "title": "A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520257",
      "title": "The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus",
      "status": "UNKNOWN",
      "last_update": "2018-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03533582",
      "title": "Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03578874",
      "title": "SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2020-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03582618",
      "title": "CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03606590",
      "title": "Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)",
      "status": "COMPLETED",
      "last_update": "2024-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722498",
      "title": "Phase \u2161 Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE",
      "status": "WITHDRAWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03730675",
      "title": "Irradiation Stent Placement Plus TACE for HCC and PVTT",
      "status": "UNKNOWN",
      "last_update": "2018-12-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03764293",
      "title": "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2024-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03775395",
      "title": "HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2019-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03780634",
      "title": "HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC",
      "status": "WITHDRAWN",
      "last_update": "2019-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03812770",
      "title": "Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03812783",
      "title": "HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC",
      "status": "UNKNOWN",
      "last_update": "2019-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04000737",
      "title": "YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2025-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04039607",
      "title": "A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04135690",
      "title": "HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial",
      "status": "UNKNOWN",
      "last_update": "2023-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04170556",
      "title": "Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)",
      "status": "COMPLETED",
      "last_update": "2024-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04229355",
      "title": "DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04317248",
      "title": "\"Cocktail\" Therapy for Hepatitis B Related Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04344158",
      "title": "A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04387695",
      "title": "SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT",
      "status": "UNKNOWN",
      "last_update": "2023-02-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04476329",
      "title": "Optimization for Regorafenib in HCC",
      "status": "TERMINATED",
      "last_update": "2021-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04568330",
      "title": "Prevention of Hand-foot Skin Reaction",
      "status": "COMPLETED",
      "last_update": "2020-09-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04611165",
      "title": "Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2025-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04709380",
      "title": "Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT",
      "status": "TERMINATED",
      "last_update": "2025-02-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04710641",
      "title": "Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone",
      "status": "COMPLETED",
      "last_update": "2025-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04720716",
      "title": "A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC",
      "status": "COMPLETED",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04723004",
      "title": "Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC",
      "status": "COMPLETED",
      "last_update": "2026-07-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04926532",
      "title": "Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04985136",
      "title": "A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)",
      "status": "TERMINATED",
      "last_update": "2022-09-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05033522",
      "title": "Immunotherapy for Advanced Liver Cancer",
      "status": "SUSPENDED",
      "last_update": "2025-10-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05117957",
      "title": "Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study",
      "status": "COMPLETED",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05121571",
      "title": "The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study",
      "status": "COMPLETED",
      "last_update": "2021-11-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135364",
      "title": "HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure",
      "status": "UNKNOWN",
      "last_update": "2021-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05391867",
      "title": "Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-05-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05517239",
      "title": "Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment",
      "status": "COMPLETED",
      "last_update": "2022-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05822752",
      "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06030895",
      "title": "Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.",
      "status": "COMPLETED",
      "last_update": "2024-03-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06527495",
      "title": "Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06797427",
      "title": "A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar\u00ae (sorafenib) in Healthy Volunteers",
      "status": "COMPLETED",
      "last_update": "2025-03-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07351513",
      "title": "A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB": {
    "n": 14,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05024214",
      "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05443087",
      "title": "TARGETed Therapy Drug MONITOring in DIGestive Oncology",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00247676",
      "title": "An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2010-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00361309",
      "title": "SU011248 in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "status": "COMPLETED",
      "last_update": "2019-06-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00495625",
      "title": "Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)",
      "status": "TERMINATED",
      "last_update": "2012-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00514228",
      "title": "Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00524316",
      "title": "Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2017-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00699374",
      "title": "Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2013-01-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787787",
      "title": "Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2017-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164202",
      "title": "Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01215565",
      "title": "Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma",
      "status": "TERMINATED",
      "last_update": "2014-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 14,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05024214",
      "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05443087",
      "title": "TARGETed Therapy Drug MONITOring in DIGestive Oncology",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00247676",
      "title": "An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2010-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00361309",
      "title": "SU011248 in Advanced Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "status": "COMPLETED",
      "last_update": "2019-06-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00495625",
      "title": "Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)",
      "status": "TERMINATED",
      "last_update": "2012-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00514228",
      "title": "Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00524316",
      "title": "Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2017-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00699374",
      "title": "Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2013-01-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787787",
      "title": "Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer",
      "status": "TERMINATED",
      "last_update": "2017-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164202",
      "title": "Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01215565",
      "title": "Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma",
      "status": "TERMINATED",
      "last_update": "2014-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SURUFATINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05171439",
      "title": "Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples",
      "status": "UNKNOWN",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05282433",
      "title": "Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TELATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04798781",
      "title": "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TEPOTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01988493",
      "title": "Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115373",
      "title": "c-Met Second-Line Hepatocellular Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIVANTINIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00802555",
      "title": "Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2012-07-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00827177",
      "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00988741",
      "title": "Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01178411",
      "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01656265",
      "title": "Study of ARQ 197 in Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2017-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01755767",
      "title": "Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2021-04-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02029157",
      "title": "A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIVOZANIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01807156",
      "title": "Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer",
      "status": "TERMINATED",
      "last_update": "2016-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835223",
      "title": "Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2020-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970616",
      "title": "A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00508001",
      "title": "Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "last_update": "2016-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03291379",
      "title": "Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "X-82": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03511222",
      "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}